All In Biotech

Drug Trial Radar · NCT07321652

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 466 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

466

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Sep 30, 2028

Study completion Sep 30, 2038

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving sonrotoclax and zanubrutinib may be more effective than zanubrutinib alone for the treatment of untreated CLL/SLL.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia

Interventions

  • ZanubrutinibDrug

    Given PO

  • SonrotoclaxDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scan

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Survey AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: From initial randomization date until the earlier of disease progression or death from any cause, up to 10 years

Locations

261 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Kaiser Permanente-Anaheim

    Anaheim, California · Recruiting

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California · Recruiting

  • Kaiser Permanente-Bellflower

    Bellflower, California · Recruiting

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Kaiser Permanente-Fontana

    Fontana, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente South Bay

    Harbor City, California · Recruiting

  • Kaiser Permanente-Irvine

    Irvine, California · Recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente West Los Angeles

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente- Modesto MOB II

    Modesto, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente-Ontario

    Ontario, California · Recruiting

  • Kaiser Permanente - Panorama City

    Panorama City, California · Recruiting

  • Kaiser Permanente-Riverside

    Riverside, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Downtown Commons

    Sacramento, California · Recruiting

  • Kaiser Permanente-South Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente-San Diego Zion

    San Diego, California · Recruiting

  • Kaiser Permanente-San Francisco

    San Francisco, California · Recruiting

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California · Recruiting

  • Kaiser Permanente San Leandro

    San Leandro, California · Recruiting

  • Kaiser Permanente-San Marcos

    San Marcos, California · Recruiting

  • Kaiser San Rafael-Gallinas

    San Rafael, California · Recruiting

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California · Recruiting

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California · Recruiting

  • Kaiser Permanente-South San Francisco

    South San Francisco, California · Recruiting

  • Kaiser Permanente-Vallejo

    Vallejo, California · Recruiting

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California · Recruiting

  • Kaiser Permanente-Woodland Hills

    Woodland Hills, California · Recruiting

  • UCHealth Memorial Hospital Central

    Colorado Springs, Colorado · Recruiting

  • Memorial Hospital North

    Colorado Springs, Colorado · Recruiting

  • Kaiser Permanente-Franklin

    Denver, Colorado · Recruiting

  • Grand Valley Oncology

    Grand Junction, Colorado · Recruiting

  • Kaiser Permanente-Rock Creek

    Lafayette, Colorado · Recruiting

  • Kaiser Permanente-Lone Tree

    Lone Tree, Colorado · Recruiting

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

Showing 40 of 261 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.